Dueholmhewitt6456

Modified WJD can be used to treat CCBS by improving microcirculation in reproductive organs.OBJECTIVE To investigate the immunomodulatory mechanism by which Yangfei Huoxue decoction (YHD) alleviates bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats. METHODS Rats were randomly divided into two time-point groups (day 14 and 28), and each time-point group comprised the following six subgroups control, BLM, dexamethasone (DXM), YHD high dose (YHD-H), YHD middle dose (YHD-M), and YHD low dose (YHD-L). Haematoxylin and eosin and Masson staining, flow cytometry, enzyme-linked immunosorbent assay, Western blotting and UPLC-QT of analyses were examined. RESULTS The results showed that YHD reduced the degree of alveolar inflammation and fibrosis; downregulated the expression of CD28, CD80, CD86, Delta-like 1, Notch2, and Notch3; and upregulated the proportions of Th1/Th2 and Tc1/Tc2. The seven components of YHD were detected. CONCLUSION The current study indicates that YHD mainly functions by regulating the immune system and that the molecular mechanism may be related to the regulation of the Notch signaling pathway.OBJECTIVE To determine the efficacy of a fermented buckwheat flower and leaf extract (EFBFL) for the reduction of blood glucose and lipid dysregulation in spontaneously obese type 2 diabetic db/db mice, and to explore the possible mechanisms involved. METHODS Forty 9-week-old male db/db mice were randomly allocated to a high-dose EFBFL group (EFBFL-H), a low-dose EFBFL group (EFBFL-L), a metformin hydrochloride positive control group (MEG), and a db/db control group (MG), and there was also a db/m negative control group (NCG) (n = 10). Oral glucose tolerance tests (OGTT) were performed after 7 weeks of treatment. At the end of 8 weeks of treatment, random blood glucose (RBG), glycosylated hemoglobin (HbAlc), fasting plasma glucose (FPG), fasting serum insulin (FINS) , triglyceride (TG), serum total cholesterol (TC), free fatty acids (FFA), high-density lipoprotein-cholesterol, and low-density lipoprotein-cholesterol (LDL-c) were measured, the homeostasis model assessment-insulin resistance (HOMA-IR) was calculated. Immunohistochemistry and western blotting measured the expression of glucose transporter4 (GLUT4) and peroxisome proliferator-activated receptor γ (PPAR-γ) by in skeletal muscle. RESULTS The MG mice had a significantly increased in RBG, HbAlc, the HOMA-IR level, the serum of TG, TC, LDL-c, but a decreased in glucose tolerance and the protein expression of GLUT4 and PPAR-γ compared with the NCG. Compared with the MG, EFBFL groups significantly decreased RBG, HbAlc, and the HOMA-IR level, increased glucose tolerance. Meanwhile EFBFL groups reduced the serum TG, TC, and LDL-c in a dose-dependent manner. In addition, EFBFL increased the protein expression of GLUT4 and PPAR-γ in the skeletal muscle of db/db mice. There was significant difference between the MG group and EFBFL groups. CONCLUSION These findings suggest that EFBFL has anti-diabetic effects in db/db mice, ameliorating glucose intolerance, lipid dysregulation, and insulin resistance.OBJECTIVE To evaluate the efficacy and safety of tonifying kidney therapy (Bushen, TK) for stable chronic obstructive pulmonary disease (COPD). METHODS Randomized controlled trials (RCTs) of TK use for treatment of stable COPD were searched in four databases including PubMed, the Cochrane Library, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure Database from inception to December 2017. Two reviewers independently screened the literature, extracted the data, and assessed the risk of bias in the included studies. RevMan 5.3 software was used for the Meta-analysis. RESULTS Eight RCTs involving 809 patients with stable COPD were included. Compared with the conventional Western Medicine (CWM) group, the TK group (TK combined with CWM) showed significant improvements in the effectiveness rates (RR = 1.37, 95% CI 1.22 to 1.53, P less then 0.000 01) and 6-min walk distance in meters (MD 11.92, 95% CI 3.52 to 20.32, P = 0.005), this study also showed that the TK group can decrease The Traditional Chinese Medicine Syndrome Score (MD -8.01, 95% CI －12.89 to －3.13, P = 0.001). The lung function [forced expiratory volume in one second% (FEV1%), FEV1/forced vital capacity] showed no difference between the TK and control groups. CONCLUSION For patients with stable COPD, TK can improve the clinical effectiveness and exercise capacity but fail to improve the patient's symptoms. Because of the low methodological quality of the included trials, additional high-quality and large-scale RCTs are required.OBJECTIVE To address the optimal Chinese herbal injections (CHIs) against liver cancer, the present network Meta-analysis is designed to investigate the comparative efficacy and safety of different CHIs. METHODS Several electronic databases were searched up to June 1st, 2017. The quality assessment was conducted and network Meta-analysis was performed to compare the efficacy and safety of different CHIs plus transcatheter hepatic arterial chemoembolization (TACE). Primary outcomes were 1-year and 2-year survival rate, the secondary outcomes includes the clinical effective rate, performance status and the adverse reactions (ADRs). Data analysis was applied Stata 13.0 and WinBUGS 1.4 software. RESULTS A total of 105 randomized controlled trials (RCTs) were identified for inclusion in this analysis, with data for 7683 patients and 13 CHIs. PH-797804 inhibitor The results suggested that Javanica oil emulsion, Huachansu injection plus TACE were more favorable for 1-year and 2-year survival rate than other CHIs. Kanglaite, Astragalus polysaccharide injection plus TACE showed superiority in the clinical effective rate and performance status over other CHIs. And Shenmai injection plus TACE was superior to reducing ADRs than other CHIs for patients with liver cancer. CONCLUSION Our findings indicated that receiving CHIs combined with TACE may have therapeutic benefits for patients with liver cancer in improving survival rate, clinical effective rate, the performance status and alleviating the ADRs.